Clock’s ticking. After an expected FDA nod for Descovy as the second HIV PrEP drug, Gilead Sciences now has one year to convince its current Truvada takers to switch over before generics hit. The FDA ...

The FDA has approved Gilead’s combination drug Descovy for HIV prophylaxis in the US, offering a way of cutting the risk of sexually acquired infection with an improved safety profile compared with ...

Descovy demonstrated continued noninferiority to Truvada for HIV pre-exposure prophylaxis and statistically significant differences over Truvada for pre-specified secondary end points. In the phase 3, ...

(Reuters) - The U.S. Food and Drug Administration on Thursday approved Gilead Sciences Inc's <GILD.O> Descovy to reduce the risk of sexually acquired HIV infection in men and transgender women who ...

Gilead Sciences, after striking a similar deal in 2014 to delay generics of its earlier HIV pre-exposure prophylaxis (PrEP) med Truvada, has followed suit on its key next-gen offering Descovy. Monday, ...

Add Yahoo as a preferred source to see more of our stories on Google. A major health insurer has notified policy holders that it will no longer cover Gilead Sciences’ drug Descovy for pre-exposure ...

Gilead announced positive results from Phase 3 studies which switched virologically suppressed HIV-1 patients from regimens containing Truvada (emtricitabine and tenofovir disoproxil fumarate ...

The panel voted against recommending the prevention pill for use in cisgender women due to inadequate data on efficacy in this patient population. An FDA panel has backed Gilead’s HIV prevention drug ...

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (NASDAQ: GILD) today presented additional results from the DISCOVER trial evaluating an investigational use of Descovy (emtricitabine 200 ...

George Froehle, PA, a primary care clinician at CentraCare in rural St. Cloud, Minnesota, has been prescribing the HIV prevention pill tenofovir disoproxil fumarate plus emtracitabine (TDF/FTC) since ...